Table 1

Summary of clinical characteristics of 10 eyes initially treated with bevacizumab for choroidal neovascularisation

Patient no.DiagnosisInitial FA features of CNVFeatures of exudationBaseline visionNo. of initial bevacizumab injectionsNo. of injections prior to response
Patients initially treated with bevacizumab
1AMDClassicSRF/CMOCF31
2AMDClassicSRF/CMO20/5061
3AMDClassicSRF20/7041
4AMDOccultSRF/PEDCF53
5AMDOccultSRF/PED20/5031
6AMDOccultSRF/CMO/PED20/60101
7AMDOccultSRF/CMO/PED20/20051
8AMDOccultSRF/CMO20/7033
9AMDOccultSRF/PED20/50122
10AMDOccultSRF/PED20/40133
Patient no.Reason for switchVision at switchNo. of subsequent ranibizumab injectionsResponse after switchNo. of injections prior to responseVision at last visit
Patients initially treated with bevacizumab
1Increasing SRF20/2004Yes1CF
2Persistent SRF20/402No20/40
3Persistent SRF20/301Yes120/30
4Increasing PED and SRF20/4008Yes1CF
5Increasing PED and SRF20/10016Yes120/50
6Persistent SRF20/306Yes120/30
7Increasing SRF and CMO20/2006Yes120/200
8Persistent SRF20/2008Yes220/50
9Persistent PED and SRF20/6011Yes320/50
10Persistent PED and SRF20/408No20/50
  • AMD, age-related macular degeneration; CF, count fingers; CMO, cystoid macular oedema; CNV, choroidal neovascularisation; FA, flourescein angiogram; PED, pigment epithelial detachment; SRF, subretinal fluid.